Indian Drugmakers Prepare for Supply Disruptions Amid Iran Conflict

India's Pharmaceutical Sector Faces Rising Costs Amid West Asia Conflict

The ongoing West Asia conflict is putting a strain on India's pharmaceutical sector, with major players warning of potential price hikes for patients and healthcare systems. Executives at Dr. Reddy's Laboratories and Cipla have expressed concerns that rising freight and raw material expenses could erode their profit margins, leading to increased costs for consumers.

According to executives, the companies are currently absorbing a significant portion of the cost increases to ensure uninterrupted supply of medicines. However, this buffer may not hold if disruptions persist. Cipla's Managing Director and Chief Executive Officer Achin Gupta noted that the longer the conflict continues, the more these costs will seep into their system, ultimately translating into pricing discussions with customers.

At Dr. Reddy's, Chief Financial Officer MV Narasimham emphasized that the company's priority is to ensure supply continuity before addressing pricing. The company is deploying multiple mitigation levers, including renegotiating logistics terms with customers and relying on inventory buffers to manage disruptions.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Executives at both companies are closely monitoring the situation and evaluating emergency contractual provisions, including force majeure clauses. Dr. Reddy's is also leveraging structural changes made in recent years, such as diversifying raw material sourcing, to reduce dependence on single sources like China.

At Cipla, the strategy mirrors a similar approach of buffering costs and ensuring supply. The company has so far avoided major supply disruptions but is starting to feel pricing pressures due to rising freight and input costs. If disruptions persist, Cipla may need to revisit pricing arrangements to protect margins.

The West Asia region acts as a critical trade corridor for Indian pharma exports, particularly through Red Sea shipping routes connecting Asia with Europe and the US. Disruptions here extend transit times, inflate freight rates, and squeeze supply chains. India's pharmaceutical trade exposure amplifies this risk, with the country exporting drugs worth roughly $31 billion in FY26 and importing $4.5 billion worth of bulk drugs and intermediates, especially from China.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

The conflict is also fueling input cost inflation, especially in chemicals such as gas and solvents. Solvents are liquid chemicals used in drug manufacturing to dissolve or process active pharmaceutical ingredients and are derived from petrochemicals, making their prices highly sensitive to crude oil movements. Unlike many raw materials, solvents and certain gases cannot be easily stockpiled for long, adding to supply vulnerability.

India's pharmaceutical sector is facing a perfect storm of rising costs and supply chain disruptions, threatening to increase prices for patients and healthcare systems.